Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) unit Suzhou Shengdia Biopharmaceutical obtained China's regulatory approval to conduct clinical trials for SHR-4595 injection.
The trial will evaluate the biological product's efficacy in treating patients with advanced malignant solid tumors, according to a Monday aftermarket filing with the Shanghai bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.